Sodium Gluconate, Gluconic Acid, and Derivative Products From China, 55739 [2018-24287]

Download as PDF Federal Register / Vol. 83, No. 216 / Wednesday, November 7, 2018 / Notices INTERNATIONAL TRADE COMMISSION [Investigation Nos. 701–TA–590 and 731– TA–1397 (Final)] Sodium Gluconate, Gluconic Acid, and Derivative Products From China amozie on DSK3GDR082PROD with NOTICES1 Determinations On the basis of the record 1 developed in the subject investigations, the United States International Trade Commission (‘‘Commission’’) determines, pursuant to the Tariff Act of 1930 (‘‘the Act’’), that an industry in the United States is materially injured by reason of imports of Sodium Gluconate, Gluconic Acid, and Derivative Products from China, provided for in subheadings 2918.16.10, 2918.16.50, and 2932.20.50 of the Harmonized Tariff Schedule of the United States, that have been found by the U.S. Department of Commerce (‘‘Commerce’’) to be sold in the United States at less than fair value (‘‘LTFV’’), and to be subsidized by the government of China. Background The Commission, pursuant to sections 705(b) and 735(b) of the Act (19 U.S.C. 1671d(b) and 19 U.S.C. 1673d(b)), instituted these investigations effective November 30, 2017, following receipt of a petition filed with the Commission and Commerce by PMP Fermentation Products (‘‘PMP’’), Inc., Peoria, Illinois. The final phase of the investigations was scheduled by the Commission following notification of preliminary determinations by Commerce that imports of Sodium Gluconate, Gluconic Acid, and Derivative Products from China were subsidized within the meaning of section 703(b) of the Act (19 U.S.C. 1671b(b)) and sold at LTFV within the meaning of 733(b) of the Act (19 U.S.C. 1673b(b)). Notice of the scheduling of the final phase of the Commission’s investigations and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register on July 18, 2018 (83 FR 33944). The hearing was held in Washington, DC, on September 18, 2018, and all persons who requested the opportunity were permitted to appear in person or by counsel. The Commission made these determinations pursuant to sections 705(b) and 735(b) of the Act (19 U.S.C. 1 The record is defined in sec. 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)). VerDate Sep<11>2014 17:46 Nov 06, 2018 Jkt 247001 1671d(b) and 19 U.S.C. 1673d(b)). It completed and filed its determinations in these investigations on October 31, 2018. The views of the Commission are contained in USITC Publication 4834 (October 2018), entitled Sodium Gluconate, Gluconic Acid, and Derivative Products from China: Investigation Nos. 701–TA–590 and 731–TA–1397 (Final). By order of the Commission. Issued: November 1, 2018. Lisa Barton, Secretary to the Commission. [FR Doc. 2018–24287 Filed 11–6–18; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical CBRN Defense Consortium Notice is hereby given that, on October 16, 2018, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), Medical CBRN Defense Consortium (‘‘MCDC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Allegheny-Singer Research Institute DBA AHN Institute, Pittsburgh, PA; Allotropic Tech, Halethorpe, MD; ASELL LLC, Owings Mills, MD; Clear Scientific LLC, Cambridge, MA; FLIR Detection, Inc., Stillwater, OK; FORGE Life Sciences, LLC, Doylestown, PA; IDBiologics, Inc., Nashville, TN; ImmPORT Therapeutics Inc. DBA Antigen Discovery Inc., Irvine, CA; Polo Custom Products, Topeka, KS; SIGA Technologies, Inc., New York, NY; The Albert Sabin Vaccine Institute, Inc. DBA Sabin Vaccine Institute, Washington, DC; VenatoRx Pharmaceuticals, Inc., Malvern, PA; and Windgap Medical, Inc., Watertown, MA, have been added as parties to this venture. Also, Artificial Cell Technologies, Inc., New Haven, CT; Celdara Medical, LLC, Lebanon, NH; HORIBA Instruments, Inc., Edison, NY; Macromoltek, Austin, TX; Philips Healthcare, Andover, MA; Phosphorex Inc., Hopkinton, MA; PPD Development LP, Wilmington, NC; Sequoia PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 55739 Consulting Group, LLC, Lake Forest, CA; and University of Tennessee, Knoxville, Knoxville, TN, have withdrawn as parties to this venture. No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and MCDC intends to file additional written notifications disclosing all changes in membership. On November 13, 2015, MCDC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the Federal Register pursuant to Section 6(b) of the Act on January 6, 2016 (81 FR 513). The last notification was filed with the Department on August 3, 2018. A notice was published in the Federal Register pursuant to Section 6(b) of the Act on August 24, 2018 (83 FR 42940). Suzanne Morris, Chief, Premerger and Division Statistics Unit, Antitrust Division. [FR Doc. 2018–24335 Filed 11–6–18; 8:45 am] BILLING CODE 4410–11–P DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993—National Spectrum Consortium Notice is hereby given that, on October 29, 2018, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (‘‘the Act’’), National Spectrum Consortium (‘‘NSC’’) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Geon Technologies, LLC, Columbia, MD; Herrick Technology Laboratories, Inc., Germantown, MD; T2S, LLC, Whiteford, MD; GenXComm, Inc., Austin, TX; Beatty and Company Computing, Inc., Rancho Santa Fe, CA; Baylor University, Waco, TX; Applied Engineering Concepts, Inc., Eldersburg, MD; and OST, Inc., McLean, VA, have been added as parties to this venture. Also, Interoptek, Inc., N. Charleston, SC; Kranze Technology Solutions, Inc., Prospect Heights, IL; and G5 Scientific, E:\FR\FM\07NON1.SGM 07NON1

Agencies

[Federal Register Volume 83, Number 216 (Wednesday, November 7, 2018)]
[Notices]
[Page 55739]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-24287]



[[Page 55739]]

-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation Nos. 701-TA-590 and 731-TA-1397 (Final)]


Sodium Gluconate, Gluconic Acid, and Derivative Products From 
China

Determinations

    On the basis of the record \1\ developed in the subject 
investigations, the United States International Trade Commission 
(``Commission'') determines, pursuant to the Tariff Act of 1930 (``the 
Act''), that an industry in the United States is materially injured by 
reason of imports of Sodium Gluconate, Gluconic Acid, and Derivative 
Products from China, provided for in subheadings 2918.16.10, 
2918.16.50, and 2932.20.50 of the Harmonized Tariff Schedule of the 
United States, that have been found by the U.S. Department of Commerce 
(``Commerce'') to be sold in the United States at less than fair value 
(``LTFV''), and to be subsidized by the government of China.
---------------------------------------------------------------------------

    \1\ The record is defined in sec. 207.2(f) of the Commission's 
Rules of Practice and Procedure (19 CFR 207.2(f)).
---------------------------------------------------------------------------

Background

    The Commission, pursuant to sections 705(b) and 735(b) of the Act 
(19 U.S.C. 1671d(b) and 19 U.S.C. 1673d(b)), instituted these 
investigations effective November 30, 2017, following receipt of a 
petition filed with the Commission and Commerce by PMP Fermentation 
Products (``PMP''), Inc., Peoria, Illinois. The final phase of the 
investigations was scheduled by the Commission following notification 
of preliminary determinations by Commerce that imports of Sodium 
Gluconate, Gluconic Acid, and Derivative Products from China were 
subsidized within the meaning of section 703(b) of the Act (19 U.S.C. 
1671b(b)) and sold at LTFV within the meaning of 733(b) of the Act (19 
U.S.C. 1673b(b)). Notice of the scheduling of the final phase of the 
Commission's investigations and of a public hearing to be held in 
connection therewith was given by posting copies of the notice in the 
Office of the Secretary, U.S. International Trade Commission, 
Washington, DC, and by publishing the notice in the Federal Register on 
July 18, 2018 (83 FR 33944). The hearing was held in Washington, DC, on 
September 18, 2018, and all persons who requested the opportunity were 
permitted to appear in person or by counsel.
    The Commission made these determinations pursuant to sections 
705(b) and 735(b) of the Act (19 U.S.C. 1671d(b) and 19 U.S.C. 
1673d(b)). It completed and filed its determinations in these 
investigations on October 31, 2018. The views of the Commission are 
contained in USITC Publication 4834 (October 2018), entitled Sodium 
Gluconate, Gluconic Acid, and Derivative Products from China: 
Investigation Nos. 701-TA-590 and 731-TA-1397 (Final).

    By order of the Commission.

    Issued: November 1, 2018.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2018-24287 Filed 11-6-18; 8:45 am]
 BILLING CODE 7020-02-P